Abstract
Renal cell carcinoma (RCC) is the most common malignancy arising in the adult kidney, representing 2% of all malignancies and 2% of cancer-related deaths. It is the 10th most common cancer in the U.S., where it causes more than 12,000 deaths per year. Its incidence has been increasing, a phenomenon that cannot be accounted for by the wider use of imaging procedures (1). RCC is more common in men than women, especially in men over 55 yr of age. Risk factors include genetic predisposition (2), hypertension, obesity (3),and occupational exposures (4). RCC may be as small as 1 cm in diameter when discovered (usually incidentally), or as bulky as several kilograms. It most often manifests with pain, as a palpable mass, as hematuria, or as another paraneoplastic syndrome.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Chow, W. H., Devesa, S. S., Warren, J. L., and Fraumeni, J. F., Jr. (1999) Rising incidence of renal cell cancer in the United States. JAMA 281, 1628–1631.
Takahashi, M., Kahnoski, R., Gross, D., Nicol, D., and Teh, B. T. (2002) Familial adult renal neoplasia. J. Med. Genet. 39, 1–5.
Chow, W. H., Gridley, G., Fraumeni, J. F., Jr., and Jarvholm, B. (2000) Obesity, hypertension, and the risk of kidney cancer in men. N. Engl. J. Med. 343, 1305–1311.
Moyad, M. A. (2001) Review of potential risk factors for kidney (renal cell) cancer. Semin. Urol. Oncol. 19, 280–293.
Mostofi, F. K. and Davis, C. J. (1998) International Histological Classification of Tumors. Springer, Berlin.
Bugert, P. and Kovacs, G. (1996) Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am. J. Pathol. 149, 2081–2088.
Storkel, S., Eble, J. N., Adlakha, K., et al. (1997) Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80, 987–989.
Presti, J. C., Jr., Moch, H., Reuter, V. E., Huynh, D., and Waldman, F. M. (1996) Comparative genomic hybridization for genetic analysis of renal oncocytomas. Genes Chromosom. Cancer 17, 199–204.
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655–1659.
Kish, J. A., Wolf, M., Crawford, E. D., et al. (1994) Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74, 916–919.
Einzig, A. I., Gorowski, E., Sasloff, J., and Wiernik, P. H. (1991) Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest. 9, 133–136.
Fossa, S. D., Droz, J. P., Pavone-Macaluso, M. M., Debruyne, F. J., Vermeylen, K., and Sylvester, R. (1992) Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur. J. Cancer 28A, 878–880.
Atzpodien, J., Kirchner, H., Illiger, H. J., et al. (2001) IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130–1136.
Schomburg, A., Kirchner, H., Fenner, M., Menzel, T., Poliwoda, H., and Atzpodien, J. (1993) Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. Eur. J. Cancer 29A, 737–740.
Minasian, L. M., Motzer, R. J., Gluck, L., Mazumdar, M., Vlamis, V., and Krown, S. E. (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11, 1368–1375.
Vogelzang, N. J., Lipton, A., and Figlin, R. A. (1993) Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J. Clin. Oncol. 11, 1809–1816.
Atkins, M. B., Sparano, J., Fisher, R. I., et al. (1993) Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J. Clin. Oncol. 11, 661–670.
Ellerhorst, J. A., Sella, A., Amato, R. J., et al. (1997) Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80, 2128–2132.
Childs, R., Chernoff, A., Contentin, N., et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750–758.
Levy, D. A., Slaton, J. W., Swanson, D. A., and Dinney, C. P. (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. 159, 1163–1167.
Ljungberg, B., Alamdari, F. I., Rasmuson, T., and Roos, G. (1999) Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 84, 405–411.
Hermanek, P. and Schrott, K. M. (1990) Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma../. Urol. 144, 238–242.
Henson, D. E., Fielding, L. P., Grignon, D. J., et al. (1995) College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee. Arch. Pathol. Lab. Med. 119, 1109–1112.
Tsui, K. H., Shvarts, O., Smith, R. B., Figlin, R. A., deKernion, J. B., and Belldegrun, A. (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J. Urol. 163, 1090–1095.
Gettman, M. T., Blute, M. L., Spotts, B., Bryant, S. C., and Zincke, H. (2001) Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 91, 354–361.
Moch, H., Gasser, T., Amin, M. B., Torhorst, J., Sauter, G., and Mihatsch, M. J. (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89, 604–614.
Ono, K., Tanaka, T., Tsunoda, T., et al. (2000) Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 60, 5007–5011.
Golub, T. R., Slonim, D. K., Tamayo, P., et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537.
Hedenfalk, I., Duggan, D., Chen, Y., et al. (2001) Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539–548.
Okabe, H., Satoh, S., Kato, T., et al. (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61, 2129–2137.
Alizadeh, A. A., Eisen, M. B., Davis, R. E., et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511.
Sorlie, T., Perou, C. M., Tibshirani, R., et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10,869–10, 874.
Bhattacharjee, A., Richards, W. G., Staunton, J., et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 98, 13,790–13, 795.
Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436–442.
Moch, H., Schraml, P., Bubendorf, L., et al. (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol. 154, 981–986.
Dierick, A. M., Praet, M., Roels, H., Verbeeck, P., Robyns, C., and Oosterlinck, W. (1991) Vimentin expression of renal cell carcinoma in relation to DNA content and histological grading: a combined light microscopic, immunocytochemical and cytophotometrical analysis. Histopathology 18, 315–322.
Beham, A., Ratschek, M., Zatloukal, K., Schmid, C., and Denk, H. (1992) Distribution of cytokeratins, vimentin and desmoplakins in normal renal tissue, renal cell carcinomas and oncocytoma as revealed by immunofluorescence microscopy. Virchows Arch. A Pathol. Anat. Histopathol. 421, 209–215.
Young, A. N., Amin, M. B., Moreno, C. S., et al. (2001) Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am. J. Pathol. 158, 1639–1651.
Eisen, M. B., Spellman, P. T., Brown, P. 0., and Botstein, D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14, 86314, 868.
Heyer, L. J., Kruglyak, S., and Yooseph, S. (1999) Exploring expression data: identification and analysis of coexpressed genes. Genome Res. 9, 1106–1115.
Bindels, R. J., Timmermans, J. A., Hartog, A., Coers, W., and van Os, C. H. (1991) Calbindin-D9k and parvalbumin are exclusively located along basolateral membranes in rat distal nephron. J. Am. Soc. Nephrol. 2, 1122–1129.
Valore, E. V., Park, C. H., Quayle, A. J., Wiles, K. R., McCray, P. B., Jr., and Ganz, T. (1998) Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J. Clin. Invest. 101, 1633–1642.
Khoo, S. K., Bradley, M., Wong, F. K., Hedblad, M. A., Nordenskjold, M., and Teh, B. T. (2001) Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12–811.2. Oncogene 20, 5239–5242.
Boer, J. M., Huber, W. K., Sultmann, H., et al. (2001) Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 11, 1861–1870.
Takahashi, M., Rhodes, D. R., Furge, K. A., et al. (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl. Acad. Sci. USA 98, 9754–9759.
Saito, K., Saito, T., Draganac, P. S., et al. (1985) Secretion of ceruloplasmin by a human clear cell carcinoma maintained in nude mice. Biochem. Med. 33, 45–52.
Pejovic, M., Djordjevic, V., Ignjatovic, I., Stamenic, T., and Stefanovic, V. (1997) Serum levels of some acute phase proteins in kidney and urinary tract urothelial cancers. Int. Urol. Nephrol. 29, 427–432.
Kirschmann, D. A., Seftor, E. A., Nieva, D. R., Mariano, E. A., and Hendrix, M. J. (1999) Differentially expressed genes associated with the metastatic phenotype in breast cancer. Breast Cancer Res. Treat. 55, 127–136.
Thompson, T. C. (1998) Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev. 17, 439–442.
Zhang, J. C., Claffey, K., Sakthivel, R., et al. (2000) Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J. 14, 2589–2600.
Janssen, A. M., van Duijn, W., Oostendorp-Van De Ruit, M. M., et al. (2000) Metallothionein in human gastrointestinal cancer [in process citation]. J. Pathol. 192, 293–300.
Nguyen, A., Jing, Z., Mahoney, P. S., et al. (2000) In vivo gene expression profile analysis of metallothionein in renal cell carcinoma. Cancer Lett. 160, 133–140.
Izawa, J. I., Moussa, M., Cherian, M. G., Doig, G., and Chin, J. L. (1998) Metallothionein expression in renal cancer. Urology 52, 767–772.
Zhu, Y. Y., Takashi, M., Miyake, K., and Kato, K. (1991) An immunochemical and immunohistochemical study of aldolase isozymes in renal cell carcinoma. J. Urol. 146, 469–472.
Xiang, Y. Y., Ladeda, V., and Filmus, J. (2001) Glypican-3 expression is silenced in human breast cancer. Oncogene 20, 7408–7412.
Cano-Gauci, D. F., Song, H. H., Yang, H., et al. (1999) Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-GolabiBehmel syndrome. J. Cell Biol. 146, 255–264.
Ashburner, M., Ball, C. A., Blake, J. A., et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25–29.
Rhodes, D. R., Miller, J. C., Haab, B. B., and Furge, K. A. (2002) CIT: identification of differentially expressed clusters of genes from microarray data. Bioinformatics 18, 205–206.
Engel, J. D., Kundu, S. D., Yang, T., et al. (1999) Transforming growth factor-beta type II receptor confers tumor suppressor activity in murine renal carcinoma (Renca) cells. Urology 54, 164–170.
Bachman, K. E., Herman, J. G., Corn, P. G., et al. (1999) Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res. 59, 798–802.
Ahonen, M., Baker, A. H., and Kahari, V. M. (1998) Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 58, 2310–2315.
Parry, L., Maynard, J. H., Patel, A., et al. (2001) Analysis of the TSC1 and TSC2 genes in sporadic renal cell carcinomas. Br. J. Cancer 85, 1226–1230.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Takahashi, M., Teh, B.T. (2003). Gene Expression Profiling of Renal Cell Carcinoma and its Clinical Implications. In: Ladanyi, M., Gerald, W.L. (eds) Expression Profiling of Human Tumors. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-386-6_13
Download citation
DOI: https://doi.org/10.1007/978-1-59259-386-6_13
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-375-6
Online ISBN: 978-1-59259-386-6
eBook Packages: Springer Book Archive